Communications Biology · 2021 · 60 citations · 33 references
MedicineNeurobiologyNeuroscienceGene TherapyMolecular NeurobiologyMolecular NeuroscienceCharcot-marie-tooth DiseaseNanomedicineNerve RegenerationNeural RegenerationNeurodegenerative DiseasesNeurodegenerative DisordersKnockout Mouse ModelsMyelin BiologyMyelin IntegrityMyelin RegenerationNeurofilament ProteinsPeripheral Nerve RegenerationRegenerative NanomaterialsTransgenic Mouse Models
Charcot-Marie-Tooth disease type 1 A (CMT1A) lacks an effective treatment. We provide a therapy for CMT1A, based on siRNA conjugated to squalene nanoparticles (siRNA PMP22-SQ NPs). Their administration resulted in normalization of Pmp22 protein levels, restored locomotor activity and electrophysiological parameters in two transgenic CMT1A mouse models with different severity of the disease. Pathological studies demonstrated the regeneration of myelinated axons and myelin compaction, one major step in restoring function of myelin sheaths. The normalization of sciatic nerve Krox20, Sox10 and neurofilament levels reflected the regeneration of both myelin and axons. Importantly, the positive effects of siRNA PMP22-SQ NPs lasted for three weeks, and their renewed administration resulted in full functional recovery. Beyond CMT1A, our findings can be considered as a potent therapeutic strategy for inherited peripheral neuropathies. They provide the proof of concept for a new precision medicine based on the normalization of disease gene expression by siRNA.
33
Rational siRNA design for RNA interference
Angela Reynolds, Devin Leake, Queta Boese et al. · Nature Biotechnology · 2004 · 2.1K citations
Analysis of gene function in somatic mammalian cells using small interfering RNAs
Sayda M. Elbashir · Methods · 2002 · 1.1K citations · Full text
Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury
Alice Gaudin, Müge Yemişçi, Hakan Eroğlu et al. · Nature Nanotechnology · 2014 · 251 citations · Full text
Medicine, Neurology, Neuroscience +14